Volume 87 Issue 50 | p. 4 | Letters
Issue Date: December 14, 2009

Stopping Metastatic Cancer

Department: Letters

ACS 2008 IRS Form 990 Available

The American Chemical Society's 2008 Form 990 is now available on ACS's website. To access the information, go to www.acs.org and follow these instructions: click on "About Us," then click on "ACS Financial Information." Go to the heading, "ACS IRS Form 990," (PDF link) and please see also the related "Guide to Schedule J" (PDF link) for explanatory information regarding ACS Executive Compensation. If you have any access problems, contact webmaster@acs.org.

The Business Insights "Missing the Target," didn't include cancer vaccines as a means of stopping deadly metastatic cancer by simply preventing metastasis early enough and in the right patient population (C&EN, Oct. 26, page 20). Solid cancers today must be separated into two diseases. The first is primary cancer, such as breast, ovarian, prostate, colorectal, melanoma, pancreatic, and lung cancers, which are basically "cured" by a combination of surgery and chemotherapy and/or radiation. In more than 92% of cases, it is not the primary tumor but metastatic cancer that kills. Prevent metastatic cancer in patients cured of primary cancer, and you save thousands of lives and millions of dollars annually.

Cancer vaccines such as carcinoembryonic antigen (CEA) types can possibly prevent metastatic cancer if given to the appropriate patients; that is, to resected stage 3 patients who have just finished chemotherapy and/or radiation. At this time, any remaining chemo-resistant cancer cells are still very small, few in number, and, we hope, vulnerable to even small immune boosts from CEA-type vaccines.

However, for the past 10 years, there has been no work with stage 3 patients, but only with stage 4 patients with full-blown metastatic cancer. In these stage 4 patients, CEA-type vaccines work only marginally, if at all. This would be expected, because in stage 4 the tumors are too large and widespread for any cancer vaccine to work effectively. Most, if not all, cancer experts publishing in this area, state that stage 3 patients (post-chemo/radiation) are the best patients to test with cancer vaccines because "disease is minimal," but no one is willing to cross that line from stage 4 to stage 3 testing.

Reasons are unclear, but most likely high profits are involved. Safety concerns are not reasonable excuses, because 10 years of stage 4 clinical trials with CEA-type vaccines have shown these vaccines to be safe. Metastatic cancer over decades is proving itself incurable, but "preventing" the deadly disease may not be so difficult now that we know and can attack these "seeds of metastasis."

John Stoddard
Gulf Breeze, Fla.

 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment